152 related articles for article (PubMed ID: 21805043)
1. Histone deacetylase inhibitor enhances the anti-tumor effect of gemcitabine: a special reference to gene-expression microarray analysis.
Iwahashi S; Shimada M; Utsunomiya T; Morine Y; Imura S; Ikemoto T; Mori H; Hanaoka J; Saito Y
Oncol Rep; 2011 Nov; 26(5):1057-62. PubMed ID: 21805043
[TBL] [Abstract][Full Text] [Related]
2. The Histone Deacetylase Inhibitor Valproic Acid Sensitizes Gemcitabine-Induced Cytotoxicity in Gemcitabine-Resistant Pancreatic Cancer Cells Possibly Through Inhibition of the DNA Repair Protein Gamma-H2AX.
Wang Y; Kuramitsu Y; Kitagawa T; Tokuda K; Baron B; Akada J; Nakamura K
Target Oncol; 2015 Dec; 10(4):575-81. PubMed ID: 25940934
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylase inhibitor augments anti-tumor effect of gemcitabine and pegylated interferon-α on pancreatic cancer cells.
Iwahashi S; Shimada M; Utsunomiya T; Morine Y; Imura S; Ikemoto T; Mori H; Hanaoka J; Sugimoto K; Saito Y
Int J Clin Oncol; 2011 Dec; 16(6):671-8. PubMed ID: 21556798
[TBL] [Abstract][Full Text] [Related]
4. HDAC inhibitors, trichostatin A and valproic acid, increase E‑cadherin and vimentin expression but inhibit migration and invasion of cholangiocarcinoma cells.
Wang JH; Lee EJ; Ji M; Park SM
Oncol Rep; 2018 Jul; 40(1):346-354. PubMed ID: 29767267
[TBL] [Abstract][Full Text] [Related]
5. Effect of histone deacetylase inhibitor in combination with 5-fluorouracil on pancreas cancer and cholangiocarcinoma cell lines.
Iwahashi S; Ishibashi H; Utsunomiya T; Morine Y; Ochir TL; Hanaoka J; Mori H; Ikemoto T; Imura S; Shimada M
J Med Invest; 2011 Feb; 58(1-2):106-9. PubMed ID: 21372494
[TBL] [Abstract][Full Text] [Related]
6. PPARγ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells.
Koga H; Selvendiran K; Sivakumar R; Yoshida T; Torimura T; Ueno T; Sata M
Int J Oncol; 2012 Mar; 40(3):679-85. PubMed ID: 22020928
[TBL] [Abstract][Full Text] [Related]
7. Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis.
Stamatopoulos B; Meuleman N; De Bruyn C; Mineur P; Martiat P; Bron D; Lagneaux L
Leukemia; 2009 Dec; 23(12):2281-9. PubMed ID: 19710697
[TBL] [Abstract][Full Text] [Related]
8. Valproic acid enhances the anti-tumor effect of pegylated interferon-α towards pancreatic cancer cell lines.
Sugimoto K; Shimada M; Utsunomiya T; Morine Y; Imura S; Ikemoto T; Iwahashi S
Anticancer Res; 2014 Jul; 34(7):3403-9. PubMed ID: 24982347
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of TrkB Expression and Signaling by Valproic Acid and Other Histone Deacetylase Inhibitors.
Dedoni S; Marras L; Olianas MC; Ingianni A; Onali P
J Pharmacol Exp Ther; 2019 Sep; 370(3):490-503. PubMed ID: 31308194
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the anticancer properties of a novel valproic acid prodrug to leading histone deacetylase inhibitors.
Tarasenko N; Chekroun-Setti H; Nudelman A; Rephaeli A
J Cell Biochem; 2018 Apr; 119(4):3417-3428. PubMed ID: 29135083
[TBL] [Abstract][Full Text] [Related]
11. Emodin reverses gemcitabine resistance in pancreatic cancer cells via the mitochondrial apoptosis pathway in vitro.
Liu DL; Bu H; Li H; Chen H; Guo HC; Wang ZH; Tong HF; Ni ZL; Liu HB; Lin SZ
Int J Oncol; 2012 Apr; 40(4):1049-57. PubMed ID: 22159556
[TBL] [Abstract][Full Text] [Related]
12. Alterations of the gene expression profile in renal cell carcinoma after treatment with the histone deacetylase-inhibitor valproic acid and interferon-alpha.
Juengel E; Bhasin M; Libermann T; Barth S; Michaelis M; Cinatl J; Jones J; Hudak L; Jonas D; Blaheta RA
World J Urol; 2011 Dec; 29(6):779-86. PubMed ID: 20640575
[TBL] [Abstract][Full Text] [Related]
13. Impact of histone deacetylase inhibitor valproic acid on the anticancer effect of etoposide on neuroblastoma cells.
Groh T; Hrabeta J; Poljakova J; Eckschlager T; Stiborova M
Neuro Endocrinol Lett; 2012; 33 Suppl 3():16-24. PubMed ID: 23353839
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis.
Laengle J; Kabiljo J; Hunter L; Homola J; Prodinger S; Egger G; Bergmann M
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31940587
[TBL] [Abstract][Full Text] [Related]
15. Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.
Nakajima Y; Takagi H; Kakizaki S; Horiguchi N; Sato K; Sunaga N; Mori M
Anticancer Res; 2012 Dec; 32(12):5251-62. PubMed ID: 23225424
[TBL] [Abstract][Full Text] [Related]
16. [Possibilities of epigenetic anti-tumor therapy in in-vitro models].
Kovalëv RA; Stam TA; Ibatulin FM; Bondarev GN; Filatov MV
Vopr Onkol; 2012; 58(6):800-7. PubMed ID: 23600307
[TBL] [Abstract][Full Text] [Related]
17.
Samankul A; Senawong G; Utaiwat S; Prompipak J; Woranam K; Phaosiri C; Sripa B; Senawong T
Medicina (Kaunas); 2023 Jul; 59(7):. PubMed ID: 37512080
[No Abstract] [Full Text] [Related]
18. Sodium valproate potentiates staurosporine-induced apoptosis in neuroblastoma cells via Akt/survivin independently of HDAC inhibition.
Shah RD; Jagtap JC; Mruthyunjaya S; Shelke GV; Pujari R; Das G; Shastry P
J Cell Biochem; 2013 Apr; 114(4):854-63. PubMed ID: 23097134
[TBL] [Abstract][Full Text] [Related]
19. Phospho-valproic acid (MDC-1112) reduces pancreatic cancer growth in patient-derived tumor xenografts and KPC mice: enhanced efficacy when combined with gemcitabine.
Luo D; Digiovanni MG; Wei R; Lacomb JF; Williams JL; Rigas B; Mackenzie GG
Carcinogenesis; 2020 Jul; 41(7):927-939. PubMed ID: 31584613
[TBL] [Abstract][Full Text] [Related]
20. Additive Interaction of Cisplatin and Histone Deacetylase Inhibitors Combined Treatment in Rhabdomyosarcoma Cells - An Isobolographic Analysis.
Jarząb A; Łuszczki JJ; Guz M; Gumbarewicz E; Polberg K; Stepulak A
Anticancer Res; 2017 Mar; 37(3):1067-1074. PubMed ID: 28314266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
